DOCSLIB.ORG

AX Pharmaceutical Corp Product List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

AX Pharmaceutical Corp Product List A 4-Aminopyridine Acetazolamine ACTH 1-24 Acyclovir Sodium Adenosine 5 Monophosphate Adenosine 5 Tri-Phosphate Disodium Salt Albendazole Alendronate Sodium USP Alternogest Aminopentamide Sulfate Aminophylline Amlodipine Besylate Amoxicillin/Clavulanate Potassium 4:1 Amoxicillin Trihydrate Amphotericin B Ampicillin Anastrozole Aripepazole Aripiprazole Atipamezole HCl Atovaquone USP Atropine Sulfate Monohydrate Avanafil Azelastine HCl B Baclofen Benazepril HCl Betahistine Dihydrochloride Betaine Hydrochloride Betamethasone Acetate Betamethasone Dipropionate Betamethasone Sodium Phosphate Betaxolol Bexarotene Bicalutamide Bimatoprost Bisacodyl Bismuth Subcarbonate Bismuth Subsalicylate Bleomycin A5 Hydrochloride Bleomycin Sulfate Bretylium Tosylate Brimonidine Brinzolamide Bromhexine Bromocriptine Mesylate Brompheniramine Maleate Budesonide Bumetanide Bupivacaine Base Bupivacaine Hydrochloride Buprenorphine Bupropion HCl Buspirone Hydrochloride Busulfan Butaphosphan Butylated Hydroxyanisole C Cabergoline Calamine Calcium Glycerophosphate Calcium Levulinate Dihydrate Capsaicin Captopril Carbamazepine Carbazochrome Carbenoxolone Carbetocin Acetate Carbidopa Carbocisteine Carboplatin Carmustine Carprofen Carvedilol Cefadroxil Hemihydrate Cefadroxil Monohydrate Cefazolin Cefazolin Sodium Cefdinir Cefotaxime Cefotetan Disodium Cefpodoxime Cefpodoxime Proxetil Ceftazidime Ceftiofur Free Acid Ceftiofur Sodium Ceftriaxone Cefuroxime (Ceftin) Celecoxib Cephalexin Base Cephalexin Monohydrate Cesium Chloride Cetirizine Hydrochloride Cetrorelix Acetate Cetyl Myristoleate Chlorambucil Chloramphenicol Chloramphenicol Palmitate Chlorobutanol Anhydrous NF Chlorobutanol Hemihydrate Chlorhexidine Acetate Chloroquine Phosphate Chloroxine Chlorpheniramine Maleate Chlorpromazine Hydrochloride Choline Chloride Cholestyramine Cidofovir Anhydrous Cidofovir Dihydrate Cimetidine Ciprofloxacin Ciprofloxacin Hydrochloride Cisapride Monohydrate Cisatracurium Besylate Cisplatine Citalopram Clarithromycin Clemastine Fumarate Clenbuterol Hydrochloride Clindamycin Hydrochloride Clindamycin Palmitate Hydrochloride Clindamycin Phosphate Clioquinol Clobetasol Propionate Clomiphene Citrate Clomipramine Hydrochloride Clonidine Hydrochloride Clopidogrel Bisulfate Cloprostenol Clotrimazole Clozapine Co-Dergocrine Mesylate Colchicine Colistimethate Conjugated Estrogens Cortisone Acetate Coumadin Creatine Citrate Cromolyn Cyanocobalamin (B12) Cyclobenzaprine HCI Cyclobenzaprine Hydrochloride Cyclophosphamide Cyclosporin A Cyproheptadine Hydrochloride Cytarabine Base D Dacarbazine Danazol Dantrolene Sodium Dapoxetine Hydrochloride Dapsone Dasatinib Daunorubicin Hydrochloride Decoquinate Demecarium Bromide Demeclocycline Deracoxib Desipramine Deslorelin Acetate Desmopressin Acetate Desonide Desoximetasone Detomidine Hydrochloride Dexamethasone Base Dexamethasone Acetate Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate Dexbrompheniramine Maleate Dexlansoprazole Dexmedetomidine Hydrochloride Dexrazoxane Dextromethorphan Dextromethorphan Hydrobromide Diazoxide Dibucaine Dibutyl Squarate Dichloroacetic Sodium Acid Dichlorphenamide Diclazuril Diclofenac Sodium Dicyclomine Hydrochloride Diethylstilbestrol Diflorasone Diflorasone Diacetate Diflucan Digitoxin Digoxin Dihydroartemisinin Dihydroergotamine Mesylate Dihydrostreptomycin Sulfate Di-isopropylamine Dichloracetate Diltiazem Diltiazem Hydrochloride Dimenhydrinate Dimethyl Dimethyl Fumarate Diminazen Diphemanil Methylsulfate Diphenhydramine Diphenhydramine Hydrochloride Dipotassium Edta Dipyrone Dipyridamole Disulfiram DMSA (2,3-Dimercaptosuccinic Acid) Dobutamine Hydrochloride Docetaxel Docusate Sodium Dolasetron Domperidone Donepezil Doxapram HCl Monohydrate Doxorubicin Hydrochloride Doxycycline Hyclate Doxycycline Monohydrate Doxylamine Doxylamine Succinate Droperidol Drospirenone Duloxetine Hydrochloride Dutasteride Dyclonine Dydrogesterone Dyphylline E Edetate Calcium Disodium Efavirenz Eledoisin Acetate Enalapril Enalapril Maleate Enfuvirtide Acetate Enrofloxacin (Base) Enrofloxacin Base 7µm Enrofloxacin Hydrochloride Entecavir Eplerenone Eptifibatide Acetate Ergoloid Mesylate Ergonovine Ergonovine Maleate Erlotinib Erlotinib Hydrochloride Erythromycin Escitalopram Oxalate Estradiol Estradiol Cypionate Estriol Etamsylate Ethambutol Hydrochloride Ethinyl Estradiol Ethylsuccinate Fluocinonide Etodolac Etomidate Etravirine Exemestane Exenatide Acetate F Famciclovir Famotidine Febantel Felbamate Fenbendazole Fenofibrate Finasteride Florfenicol Floxuridine Flubendazole Fluconazole Flucytosine Fludarabine Fludrocortisone Fludrocortisone Acetate Flumazenil Flumethasone Flumethasone Pivalate Flunarizine Hydrochloride Flunisolide Flunixin Meglumine Fluocinolone Acetonide Fluorometholone Fluoxetine HCl Fluticasone Propionate Follicle Stimulating Hormone (FSH) Formoterol Fumarate Dihydrate Foscarnet Sodium Foscarnet Sodium Hexahydrate Fosphenytoin Sodium Fumaric Acid Furosemide G Gabapentin Galantamine Gallium Nitrate Ganciclovir Gatifloxacin Gefitinib Gemfibrozil Gentamycin Sulfate Germanium Sesquioxide Ghrelin GHRP-2 Acetate GHRP-6 Acetate Glibenclamide Glipizide Glucagon Glyburide Glyceryl Palmitostearate Glycobiarsol Griseofulvin Guanabenz Acetate H HCG Heparin Sodium Histamine Histamine Dihydrochloride Histamine Diphosphate Histamine Phosphate Histrelin Acetate Homatropine Hydrobromide Homatropine Methylbromide Hyaluronidase Hyaluronic Acid Pharma Hyaluronic Acid Sodium (Food) Hyaluronic Acid Injection Hydralazine Hydrazine Sulfate Hydrochlorothiazide Hydrocortisone Hydrocortisone Acetate Hydrocortisone Butyrate Hydrocortisone Sodium Hydrocortisone Sodium Succinate Hydrolyzed Elastin Hydroxocobalamin I Ibutamoren Mesylate (MK-0677) Idoxuridine Imidocarb Imidocarb Dipropionate Imiquimod Indigotindisulfonate Sodium Indomethacin Ipamorelin Iron Sucrose Isoplupredone Acetate Isoxsuprine HCI Isoxsuprine Hydrochloride Itraconazole Ivabradine Ivermectin K Kanamycin Sulfate Ketoconazole Ketoprofen L L-Asparaginase L-Cysteine Hydrochloride Monohydrate L-Theanine Lanthanum Carbonate Lead Acetate Leflunomide Letrozole Leucovorin Leucovorin Calcium Levalbuterol Hydrochloride Levamisole Hydrochloride Levamisole Phosphate Levetiracetam Levocetirizine Hydrochloride Levodopa Levomefolate Calcium Levosulpiride Levothyroxine Sodium (T4) Lidocain HCl Lincomycin HCl Liothyronine Sodium (T3) Loratadine Lorazepam Lornoxicam Losartan Potassium Lufenuron M Marbofloxacin Mebendazole Meclofenoxate Hydrochloride Medetomidine Hydrochloride Medroxyprogestrone Acetate Mefenamic Acid Mefloquine Hydrochloride Megestrol Acetate Melengestrol Acetate Meloxicam Melphalan Memantine Memantine Hydrochloride Meperidine Meperidine Hydrochloride Mepivacaine Hydrochloride Mequinol Mercaptopurine Mercaptopurine Monohydrate Mercuric Iodide Meropenem Meropenem Sodium Mesalamine Metaflumizone Metamizole Sodium Metaproterenol Metaproterenol Sulfate Metformin Hydrochloride Methazolamide Methimazole Methlycobalamin Methocarbamol Methotrexate Base Methotrexate Sodium Methoxyestradiol Methscopolamine Methyl Folate Metronidazole Metronidazole Benzoate Mevastatin Mexiletine HCl Mexiletine Hydrochloride Miconazole Midazolam Hydrochloride Milbemycin Oxime Milrinone Minocycline Hydrochloride Minoxidil Mirtazapine Mitomycin C Mitotane Misoprostal 1% Mometason Furoate Monobenzone Montelukast Sodium Moxidectin Moxifloxacin Hydrochloride Mupirocin Mycophenolate Mofetil Myo-Inositol Trispyrophosphate (ITPP) N N-Acetyl-L-Glucosamine Naftifine Hydrochloride Nalidixic Nalmefene Hydrochloride Naphazoline Natamycin N-Butylscopolammonium Bromide Neostigmine Methylsulphate N,N-Dimethylglycine HCl Nitrofurazone USP Nitrofurantoin O Oclacitinib Base Ondansetron Hydrochloride Dihydrate Orbifloxacin Orlistat Ormetoprim Orphenadrine Citrate Oseltamivir Phosphate Oxaliplatin Oxandrolone Oxcarbazepine Oxibendazole Oxymetazoline Oxymetazoline Hydrochloride Oxytetracycline Hydrochloride Oxytocin Acetate P Paclitaxel Potassium Arsenite Pamidronate Disodium Pancuronium Bromide Pantoprazole Sodium Monohydrate Parecoxib Paromomycin Sulfate Paroxetine Paroxetine HCl Paroxetine Hydrochloride Pazopanib Pemetrexed Disodium Pemirolast Potassium Penciclovir Phenoxybenzamine Phentrolamine Mesylate Phenylbutazone Pimecrolimus Pimobendan Piperacilin Piperazine Estrone Sulfate Piroxicam Monohydrate Podophyllin Resin Poloxamer Polyhexanide Ponazuril Posaconazole Potassium Guaiacolsulfonate Hemihydrate Pramipexole Pramiracetam Pramlintide Acetate Praziquantel Prazosin HCl Prazosin Hydrochloride Prednisolone Acetate Prednisolone Anhydrous Pregabalin Procaine HCl Procarbazine HCl Promethazine Hydrochloride Proparacaine Hydrochloride Propranolol Hydrochloride Propylthiouracil Pyrantel Pamoate Pyrazinamide Pyridostigmine Bromide (Mestinon) R Raltegravir Ranitidine Ranitidine Bismuth Citrate Ranitidine Hydrochloride Rasagiline Mesylate Reserpine Resveratrol Retinoic Acid Riboflavin 5-Phosphate Rifabutin(Mycombutin) Rifampicin Rifaximin Rocuronium Bromide Ronidazole Ropivacaine HCl Ruxolitinib Phosphate S Satraplatin Secnidazole Selegiline Hydrochloride Selenium Disulfide Sermorelin Acetate Seroquel Sertraline Hydrochloride Sevelamer Sevelamer Carbonate Sevelamer Hydrochloride Sildenafil Citrate Silicone Dioxide 325 Mesh Sincalide Sirolimus Sodium Cromoglicate Sodium Deoxycholate Sodium Dichloroacetate Sodium Hyaluronate Sodium Hydroxide Sodium Oleate Sodium Phenylbutyrate Sodium Sodium Valproate Sodium Starch Glycolate Somatropine Sotalol Hydrochloride Spironolactone
Recommended publications
  • The Management of Common Skin Conditions in General Practice

    The Management of Common Skin Conditions in General Practice

    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
  • Review of Succimer for Treatment of Lead Poisoning

    Review of Succimer for Treatment of Lead Poisoning

    Review of Succimer for treatment of lead poisoning Glyn N Volans MD, BSc, FRCP. Department of Clinical Pharmacology, School of Medicine at Guy's, King's College & St Thomas' Hospitals, St Thomas' Hospital, London, UK Lakshman Karalliedde MB BS, DA, FRCA Consultant Medical Toxicologist, CHaPD (London), Health Protection Agency UK, Visiting Senior Lecturer, Division of Public Health Sciences, King's College Medical School, King's College , London Senior Research Collaborator, South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, Peradeniya, Sri Lanka. Heather M Wiseman BSc MSc Medical Toxicology Information Services, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK. Contact details: Heather Wiseman Medical Toxicology Information Services Guy’s & St Thomas’ NHS Foundation Trust Mary Sheridan House Guy’s Hospital Great Maze Pond London SE1 9RT Tel 020 7188 7188 extn 51699 or 020 7188 0600 (admin office) Date 10th March 2010 succimer V 29 Nov 10.doc last saved: 29-Nov-10 11:30 Page 1 of 50 CONTENTS 1 Summary 2. Name of the focal point in WHO submitting or supporting the application 3. Name of the organization(s) consulted and/or supporting the application 4. International Nonproprietary Name (INN, generic name) of the medicine 5. Formulation proposed for inclusion 6. International availability 7. Whether listing is requested as an individual medicine or as an example of a therapeutic group 8. Public health relevance 8.1 Epidemiological information on burden of disease due to lead poisoning 8.2 Assessment of current use 8.2.1 Treatment of children with lead poisoning 8.2.2 Other indications 9.
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • Treatment of Diseases and Conditions Mediated By

    Treatment of Diseases and Conditions Mediated By

    (19) TZZ_ ___T (11) EP 1 572 115 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 38/07 (2006.01) A61K 38/08 (2006.01) 21.01.2015 Bulletin 2015/04 A61K 38/17 (2006.01) A61K 38/38 (2006.01) (21) Application number: 03799853.1 (86) International application number: PCT/US2003/037901 (22) Date of filing: 25.11.2003 (87) International publication number: WO 2004/050023 (17.06.2004 Gazette 2004/25) (54) TREATMENT OF DISEASES AND CONDITIONS MEDIATED BY INCREASED PHOSPHORYLATION BEHANDLUNG VON ERKRANKUNGEN UND ZUSTÄNDEN,DIE DURCH ERHÖHTE PHOSPHORYLIERUNG VERMITTELT WERDEN TRAITEMENT DE MALADIES ET D’ETATS A MEDIATION DE PHOSPHORYLATION ACCRUE (84) Designated Contracting States: • JIANG B ET AL: "Phosphopeptides derived from AT BE BG CH CY CZ DE DK EE ES FI FR GB GR hen egg yolk phosvitin: effect of molecular size HU IE IT LI LU MC NL PT RO SE SI SK TR on the calcium-binding properties." BIOSCIENCE, BIOTECHNOLOGY, AND (30) Priority: 27.11.2002 US 429924 P BIOCHEMISTRY MAY 2001, vol. 65, no. 5, May 2001 (2001-05), pages 1187-1190, XP002549556 (43) Date of publication of application: ISSN: 0916-8451 14.09.2005 Bulletin 2005/37 • KATAYAMA SHIGERU ET AL: "Antioxidative stress activity of oligophosphopeptides derived (73) Proprietor: Ampio Pharmaceuticals, Inc. from hen egg yolk phosvitin in Caco-2 cells." Englewood, CO 80112 (US) JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 8 FEB 2006, vol. 54, no. 3, 8 February (72) Inventor: BAR-OR, David 2006 (2006-02-08), pages 773-778, XP002549557 Englewood, CO 80110 (US) ISSN: 0021-8561 • OKAMOTO ET AL: ’The interleukin-8 AP-1 and (74) Representative: Weber, Joachim kappa B-like sites are genetic end targets of Hoefer & Partner FK506-sensitive pathway accompanied by Patentanwälte calcium mobilization.’ JOURNAL OF Pilgersheimer Strasse 20 BIOLOGICAL CHEMISTRY vol.
  • WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T

    WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (74) Agents: CHOTIA, Meenakshi et al; K&S Partners | Intel A 25/12 (2006.01) A61K 8/11 (2006.01) lectual Property Attorneys, 4121/B, 6th Cross, 19A Main, A 25/34 (2006.01) A61K 8/49 (2006.01) HAL II Stage (Extension), Bangalore 560038 (IN). A01N 37/06 (2006.01) A61Q 5/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A O 43/12 (2006.01) A61K 31/44 (2006.01) kind of national protection available): AE, AG, AL, AM, AO 43/40 (2006.01) A61Q 19/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A01N 57/12 (2006.01) A61K 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, AOm 59/16 (2006.01) A61K 31/496 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB20 14/06 1925 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 3 June 2014 (03.06.2014) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
  • Chelating Drug Therapy: an Update

    Chelating Drug Therapy: an Update

    Open Access Austin Journal of Genetics and Genomic Research Review Article Chelating Drug Therapy: An Update Vijay Kumar1, Ashok Kumar2*, Sandeep Kumar Singh1, Manoj Kumar3, Surendra Kumar2, Dinesh Abstract 4 5 Kumar and Ragni Singh Purpose: To study the clinical effects of metal toxicity and current 1Department of Neurology, SGPGIMS, India recommendations for management, including chelation therapy, are reviewed. 2Department of Medical Genetics, SGPGIMS, India 3Department of Microbiology, SGPGIMS, India Summary: Metals are essential to many biological processes, but excess 4Department of Chemistry, Dr. R.M.L. Avadh University, of it becomes hazardous to life. These are necessary for cell growth, electron India transport chain, several enzymatic activities and response of immune systems. 5Bheem Rao Ambedkar Bihar University, India They also serve as a cofactor for several enzymes. Chelation therapy is used for clinical management of the excess of metal. However, each metal requires *Corresponding author: Ashok Kumar, Department a specific chelation agent. A chelate is a compound form between metal and a of Medical Genetics, Sanjay Gandhi Post Graduate compound that contains two or more potential ligands. A promising Fe chelator Institute of Medical Sciences, Lucknow, India is Desferrioxamine (Desferal). Penicillamine and Trientine are uses for copper Received: March 12, 2015; Accepted: April 24, 2015; chelation. Meso-2,3-Dimercaptosuccinic Acid (DMSA) and 2,3-Dimercapto- Published: April 27, 2015 Propanesulphonate (DMPS) can be used as effective chelator of mercury. Dimercaprol, edetate calcium disodium, and succimer are the three agents primarily used for chelation of lead. Conclusion: Metal toxicity remains a significant public health concern. Elimination of elevated metal ions can be achieved by proper chelation agents.
  • Changes in Tissue Gadolinium Biodistribution Measured in an Animal Model Exposed to Four Chelating Agents

    Changes in Tissue Gadolinium Biodistribution Measured in an Animal Model Exposed to Four Chelating Agents

    Japanese Journal of Radiology (2019) 37:458–465 https://doi.org/10.1007/s11604-019-00835-1 ORIGINAL ARTICLE Changes in tissue gadolinium biodistribution measured in an animal model exposed to four chelating agents Türker Acar1,6 · Egemen Kaya2 · Mustafa Deniz Yoruk3 · Neslihan Duzenli4 · Recep Selim Senturk4 · Cenk Can4 · Lokman Ozturk3 · Canberk Tomruk5 · Yigit Uyanikgil5 · Frank J. Rybicki6 Received: 17 December 2018 / Accepted: 22 March 2019 / Published online: 30 March 2019 © Japan Radiological Society 2019 Abstract Purpose This study investigated the potential to reduce gadolinium levels in rodents after repetitive IV Gadodiamide admin- istration using several chelating agents. Materials and methods The following six groups of rats were studied. Group 1: Control; Group 2: Gadodiamide only; Group 3: Meso-2,3-Dimercaptosuccinic acid (DMSA) + Gadodiamide; Group 4: N-Acetyl-L-cysteine (NAC) + Gadodiamide; Group 5: Coriandrum sativum extract + Gadodiamide; and Group 6: Deferoxamine + Gadodiamide. Brain, kidney, and blood samples were evaluated via inductively coupled plasma mass spectrometry. The brain was also evaluated histologically. Results Kidney gadolinium levels in Groups 4 and 5 were approximately double that of Group 2 (p = 0.033 for each). There was almost no calcifcation in rat hippocampus for Group 4 rodents when compared with Groups 2, 3, 5 and 6. Conclusion Our preliminary study shows that excretion to the kidney has a higher propensity in NAC and Coriandrum sati- vum groups. It may be possible to change the distribution of gadolinium by administrating several agents. NAC may lower Gadodiamide-induced mineralization in rat hippocampus. Keywords Gadolinium deposition · Dimercaptosuccinic acid · N-Acetyl-L-cysteine · Coriandrum sativum · Deferoxamine Introduction However, the safety profle of gadolinium-based agents [1] was questioned after the discovery of nephrogenic sys- Gadolinium-based contrast agents (GBCA) have been safely temic fbrosis [2], a scleroderma-like disease characterized used in diagnostic radiology since the 1980s.
  • Recommended Chelation Protocol for Children with Blls ≥45 Μg/Dl

    Recommended Chelation Protocol for Children with Blls ≥45 Μg/Dl

    The New York City Department of Health and Mental Hygiene Guidelines for Health Care Providers Recommended Chelation Protocol for Children With BLLs ≥45 μg/dL Before Providing Chelation Therapy: • Confirm the blood lead level (BLL) ≥45 μg/dL with a venous specimen processed as an emergency test unless symptoms of encephalopathy are present. • Obtain an abdominal x-ray to look for lead solid ingestion; if radio-opaque particles are found or recent ingestion is witnessed, use a cathartic. • Arrange hospitalization and chelation therapy at a facility with expertise in treating lead-poisoned children. • Provide chelation therapy in, and discharge child to, a lead-safe environment. Do not discharge until the NYC Health Department inspects the home. • Inform the NYC Health Department of the hospital admission by calling 646-632-6002. The Health Department can provide referrals to providers with expertise in treating lead intoxication and referrals to temporary lead-safe housing. Chelation Therapy For Children with Venous BLLs ≥45 μg/dL1 BLL (μg/dL) Agent, Dosage,* and Administration Special Considerations Follow-up <45 Chelation therapy not routinely recommended See Reverse for Recommended Follow-up Blood Lead Test Schedule for Children 45 to <70 • DMSA (succimer, 2,3-meso-dimercaptosuccinic acid) • Monitor for anemia, • Schedule weekly health care visits • 1050 mg DMSA / m2 / 24 hours* ÷ q8 hours PO x neutropenia, and to monitor compliance and signs of toxicity. 5 days; round dose to nearest 100 mg/day, and then hepatic toxicity. • Monitor BLLs weekly until level stabilizes, ÷ 100-mg capsules as evenly as possible for q8-hour then follow Recommended Follow-up dosing schedule.
  • Taking a Dermatological Approach to Treating Ocular Surface Diseases

    Taking a Dermatological Approach to Treating Ocular Surface Diseases

    Taking a Dermatological Approach to treating Ocular Surface Diseases MARC GLEESON | CHIEF EXECUTIVE OFFICER OIS@SECO 2020 for Meibomian Gland Dysfunction, Contact Lens Discomfort & Blepharitis Copyright© Azura Ophthalmics | Confidential Meibomian Gland Contact Lens Blepharitis Demodex Dysfunction Discomfort Patient Administered Patient Administered Patient Administered Rx Proven activity against Rx Chronic Treatment Rx Chronic Treatment Treatment applied to Demodex applied to the eyelid applied to the eyelid the eyelid Allows continuation of New Chemical Entity In Office Physician Only Contact Lens Wear Administered Rx Treatment Lid Margin Involvement Hyperkeratinization of the Gland Orifice +/- Inflammation Copyright© Azura Ophthalmics | Confidential (MGD) Reduced secretion of lipids leads to instability of the tear film Modified sebaceous (oil-producing) and drying of the ocular surface, leading to damage and the glands responsible for secreting the signs and symptoms of dry eye disease (DED). outer lipid layer (meibum) of the tear film, which lubricates the ocular Obstructive MGD is the most common cause of evaporative surface during blinking and protects dry DED,1,3 and clinical signs of obstructive MGD are present against tear evaporation1,2 in 86% of DED patients4 MGD traditionally regarded as a hypersecretory disorder associated with bacterial infection and inflammation,1 which has guided the approach to treatment, often unsuccessfully 1Blackie et al. Cornea. 2010 | 2Knop et al. Invest Ophthalmol Vis Sci. 2011 | 3Baudouin et al.
  • Effect of Chromium(VI) on Serum Iron and Removal of Its Toxicity by Combining Deferasirox and Deferiprone Chelators in Rats

    Effect of Chromium(VI) on Serum Iron and Removal of Its Toxicity by Combining Deferasirox and Deferiprone Chelators in Rats

    American Journal of Pharmacology and Toxicology 8 (4): 164-169, 2013 ISSN: 1557-4962 ©2013 Science Publication doi:10.3844/ajptsp.2013.164.169 Published Online 8 (4) 2013 (http://www.thescipub.com/ajpt.toc) Effect of Chromium(VI) on Serum Iron and Removal of its Toxicity by Combining Deferasirox and Deferiprone Chelators in Rats 1S. Jamil A. Fatemi, 1Marzieh Iranmanesh and 2Faezeh Dahooee Balooch 1Department of Chemistry, Faculty of Sciences, Islamic Azad University, Kerman Branch, Kerman, Iran 2Department of Chemistry, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran Received 2013-09-26, Revised 2013-10-21; Accepted 2013-10-30 ABSTRACT The present research is aimed to characterize the potential efficiency of two chelators after chromium(VI) administration for 60 days following two doses of 15 and 30 mg kg −1 chromium(VI) per body weight daily to male rats. However, the hypothesis that the two chelators might be more efficient as combined therapy than as single therapy in removing chromium(VI) from bood serum was considered. In this way, two known chelators deferasirox and deferiprone were chosen and tested in the acute rat model. Two chelators were given orally as a single or combined therapy for a period of one week. Chromium(VI) and iron concentrations in blood were determined by flame atomic absorption spectroscopy method. Chromium is one of the most widely used industrial metals. Several million workers worldwide are estimated to be exposed to chromium compounds in an array of industries. Chromium(VI) is more readily absorbed by both inhalation and oral routes. Ingestion of large amounts of chromium(VI) can lead to severe respiratory, cardiovascular, gastrointestinal, hepatic and renal damage and potentially death.
  • The Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island

    The Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island

    The Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island Poison Potential Antidote Acetaminophen n-Acetylcysteine [Mucomyst®] Anticholinergics Physostigmine [Antilirium®] Benzodiazepines Flumazenil [Romazicon®] Beta-adrenergic blockers Glucagon Botulinum toxin Trivalent ABE botulinum antitoxin Calcium chloride or calcium gluconate Calcium channel blockers Hyperinsulinemia-euglycemia (HIE) therapy Atropine Carbamates Pralidoxime (2-PAM) [Protopam®] Carbon monoxide Oxygen; Hyperbaric oxygen (HBO) Clonidine Naloxone [Narcan®] Cyanide Cyanide Kit (Amyl/sodium nitrite, sodium thiosulfate) Digoxin (Cardiac glycosides) Digoxin Immune FAB Ovine [Digibind®, Digifab®] Epi Pen (Epinephrine SQ) Phentolamine [Regitine®] Ethanol Ethylene glycol 4-Methylpyrazole (Fomepizole) [Antizol®] Fluoride Calcium chloride or calcium gluconate Heparins Protamine Hydrofluoric acid Calcium chloride or calcium gluconate Hydrogen sulfide Oxygen; Hyperbaric oxygen (HBO); Sodium nitrite Iodine Starch Isoniazid Pyridoxine (Vitamin B6 ) METALS Dimercaprol [BAL] Arsenic Dimercaptosuccinic acid (DMSA, succimer) [Chemet®] Bismuth Dimercaprol [BAL] Copper D-Penicillamine [Cuprimine®] Gold Dimercaprol [BAL] Iron Deferoxamine [Desferal®] Dimercaprol [BAL] Edetate calcium disodium (Calcium EDTA) Lead Dimercaptosuccinic acid (DMSA, succimer) [Chemet®] D-Penicillamine [Cuprimine®] Dimercaprol [BAL] Mercury Dimercaptosuccinic acid (DMSA, succimer) [Chemet®] Ethanol Methanol 4-Methylpyrazole (Fomepizole) [Antizol®] Methemoglobinemic agents Methylene
  • DRAFT NOTE for GUIDANCE on ORGANIC IMPURITIES in 3 ACTIVE PHARMACEUTICAL INGREDIENTS and FINISHED 4 PHARMACEUTICAL PRODUCTS 5 (July 2016)

    DRAFT NOTE for GUIDANCE on ORGANIC IMPURITIES in 3 ACTIVE PHARMACEUTICAL INGREDIENTS and FINISHED 4 PHARMACEUTICAL PRODUCTS 5 (July 2016)

    Working document QAS/15.606/Rev2 July 2016 Draft document for comment 1 2 DRAFT NOTE FOR GUIDANCE ON ORGANIC IMPURITIES IN 3 ACTIVE PHARMACEUTICAL INGREDIENTS AND FINISHED 4 PHARMACEUTICAL PRODUCTS 5 (July 2016) 6 7 DRAFT FOR COMMENT 8 Should you have any comments on the attached text, please send these to Dr Herbert Schmidt, Medicines Quality Assurance, Technologies, Standards and Norms, World Health Organization, 1211 Geneva 27, Switzerland; email: [email protected]; fax: (+41 22) 791 4730) by 16 September 2016. In order to speed up the process for receiving draft monographs and for sending comments, please let us have your email address (to [email protected]) and we will add it to our electronic mailing list. Please specify if you wish to receive monographs. 9 10 ____________________________________________________________________________________________________ 11 © World Health Organization 2016 12 All rights reserved. 13 This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The 14 draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, 15 in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and 16 member organizations) without the permission of the World Health Organization. The draft should not be displayed on any 17 website. 18 Please send any request for permission to: 19 Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies, Standards and Norms, Department of Essential 20 Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland. 21 Fax: (41-22) 791 4730; email: [email protected].